Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,431 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Esrd Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function

NCT04476849
View directory record Official record
Conditions
Healthy Volunteers, Renal Impairment
Interventions
fezolinetant
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Garden Grove, California • Rialto, California • Clearwater, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 26, 2026, 4:41 PM EDT
Recruiting Not applicable Interventional

Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients

NCT04163614
View directory record Official record
Conditions
End Stage Renal Disease, Hypertension, Extracellular Volume Overload, Intradialytic Hypotension
Interventions
IBPS-Guided Ultrafiltration
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 26, 2026, 4:41 PM EDT
Terminated Phase 3 Interventional

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate

NCT00841126
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Magnesium iron hydroxycarbonate, Lanthanum carbonate, Placebo
Drug
Lead sponsor
Ineos Healthcare Limited
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 26, 2026, 4:41 PM EDT
Completed Phase 2 Interventional

Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study

NCT06111768
View directory record Official record
Conditions
Cardiorenal Syndrome
Interventions
Dapagliflozin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 26, 2026, 4:41 PM EDT
Completed No phase listed Observational

Real-world Aliskiren Use in Diabetic Patients

NCT01393860
View directory record Official record
Conditions
Diabetes, Hypertension
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Oct 26, 2026, 4:41 PM EDT
Recruiting Not applicable Interventional

A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)

NCT06173323
View directory record Official record
Conditions
Decision Making, Shared, Family Caregiving, Chronic Kidney Disease
Interventions
ImPart - Improving Chronic Kidney Disease Decisional Partnerships
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 26, 2026, 4:41 PM EDT
Not yet recruiting Phase 1 Interventional

Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease

NCT07696962
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
ChoironeX GalKO Porcine Thymokidney
Biological
Lead sponsor
Xeno Holdings (US), LLC dba ChoironeX
Industry
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 26, 2026, 4:41 PM EDT
Active, not recruiting No phase listed Observational

AKI and Delirium Risk Prediction and Cost Burden Study

NCT07866560
View directory record Official record
Conditions
Acute Kidney Injury, Delirium
Interventions
It is observational trial with no intervention being evaluated
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
25,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 26, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

NCT00772382
View directory record Official record
Conditions
Chronic Kidney Disease, Dialysis, Hyperphosphatemia
Interventions
MCI-196
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Tarzana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 26, 2026, 4:41 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

NCT00787618
View directory record Official record
Conditions
Renal Impairment
Interventions
50 mg Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Oct 26, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Infusion of T-Regulatory Cells in Kidney Transplant Recipients (The ONE Study)

NCT02091232
View directory record Official record
Conditions
Kidney Failure, Kidney Transplant
Interventions
T Regulatory Cell Infusion
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 26, 2026, 4:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function

NCT03318809
View directory record Official record
Conditions
Heart Failure
Interventions
AMG 986
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Tustin, California • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 26, 2026, 4:41 PM EDT
Completed No phase listed Observational

Kidney Precision Medicine Project (KPMP) - COVID-19 Protocol

NCT05384899
View directory record Official record
Conditions
Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Acute Renal Injury, Acute Renal Insufficiency, Kidney Failure, Acute, Kidney Insufficiency, Acute, Renal Failure, Acute, Renal Insufficiency, Acute, Covid19, Sars-CoV-2 Infection
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 26, 2026, 4:41 PM EDT
Recruiting Phase 4 Interventional

Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age

NCT06714864
View directory record Official record
Conditions
Catheter-Related Infections
Interventions
(taurolidine and heparin) catheter lock solution, Standard of Care
Drug
Lead sponsor
CorMedix Therapeutics
Industry
Eligibility
Up to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 26, 2026, 4:41 PM EDT
Withdrawn No phase listed Observational

A Zero Acute Kidney Injury Strategy for Percutaneous Coronary Intervention in Patients With ChronicKidney Disease

NCT04928092
View directory record Official record
Conditions
Acute Kidney Injury, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
Standard of care Ultra Low Contrast PCI
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 26, 2026, 4:41 PM EDT
Withdrawn Phase 1 Interventional

A Study of Zidovudine in HIV-Infected Patients With Kidney Problems

NCT00000685
View directory record Official record
Conditions
HIV Infections, Kidney Disease
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 26, 2026, 4:41 PM EDT
Completed Not applicable Interventional Results available

Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula

NCT02414204
View directory record Official record
Conditions
Improve Endothelial Function and Decrease Vascular Stenosis
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 26, 2026, 4:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

NCT00750620
View directory record Official record
Conditions
Renal Impairment
Interventions
YM178
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 79 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Anaheim, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 26, 2026, 4:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers

NCT02098187
View directory record Official record
Conditions
Glomerular Filtration Rate, Acute Kidney Injury
Interventions
Below target dose MP-3180, At target dose MP-3180, 2 times above target dose MP-3180, 4 times above target dose MP-3180, ORFM prototype, Iohexol comparator
Drug · Device · Other
Lead sponsor
MediBeacon
Industry
Eligibility
22 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 26, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01473420
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease
Interventions
Epoetin Hospira, Epogen Amgen
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
73
States / cities
Azusa, California • Bakersfield, California • Long Beach, California + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 26, 2026, 4:41 PM EDT
Completed No phase listed Observational

Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications

NCT02695082
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
539,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 26, 2026, 4:41 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

NCT07315360
View directory record Official record
Conditions
Renal Impairment, Healthy
Interventions
PF-07328948
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
4
States / cities
Lake Forest, California • Orlando, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 26, 2026, 4:41 PM EDT
Completed Phase 4 Interventional Results available

Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

NCT00369382
View directory record Official record
Conditions
Graft Rejection, Kidney Failure
Interventions
cyclosporine or tacrolimus, sirolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
8
States / cities
Tampa, Florida • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 26, 2026, 4:41 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

NCT01359579
View directory record Official record
Conditions
Renal Impairment
Interventions
varespladib methyl
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 26, 2026, 4:41 PM EDT